-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Pharmaceutical Network News on June 4 A few days ago, Quanyao.
com released the "Notice on Carrying out Part One of the Pharmaceutical Group Procurement Catalogue of Shenzhen Public Hospitals (Second Batch) (1) 2021 Pharmaceutical Group Procurement Registration", Shenzhen GPO's second Batch catalog procurement was officially launched.
com released the "Notice on Carrying out Part One of the Pharmaceutical Group Procurement Catalogue of Shenzhen Public Hospitals (Second Batch) (1) 2021 Pharmaceutical Group Procurement Registration", Shenzhen GPO's second Batch catalog procurement was officially launched.
According to the documents, the registration date is May 28th-June 7th, 2021 at 17:30.
According to combing, this GPO involves 140 varieties and 154 product specifications.
Among them, injections account for more than half, involving 75 product specifications and 70 varieties.
Followed by oral regular-release agents, involving 49 varieties.
According to combing, this GPO involves 140 varieties and 154 product specifications.
Among them, injections account for more than half, involving 75 product specifications and 70 varieties.
Followed by oral regular-release agents, involving 49 varieties.
The Group Purchasing Organization (GPO) is a third-party intermediary organization for social procurement.
By providing product bidding services, it can obtain lower prices than a single hospital procurement and help hospitals save procurement costs.
At the same time, through the provision of specialization, standardization of supply chain management services to help pharmaceutical production enterprises and hospitals together to improve supply chain operational efficiency, reduce operating costs, bring more revenue for the hospital.
By providing product bidding services, it can obtain lower prices than a single hospital procurement and help hospitals save procurement costs.
At the same time, through the provision of specialization, standardization of supply chain management services to help pharmaceutical production enterprises and hospitals together to improve supply chain operational efficiency, reduce operating costs, bring more revenue for the hospital.
As a pioneer in GPO procurement, Shanghai has completed three batches of volume procurement since it launched the first batch of GPOs in December 2014.
Analysis data shows that the average price drop is 79.
5% in the first batch, 74.
1% in the second batch, and 41.
7% in the third batch.
This article uses the first batch of cefuroxime axetil tablets, the second batch of nimesulide dispersible tablets and valacyclovir hydrochloride tablets, and the third batch of rosuvastatin calcium tablets and aripiprazole tablets in recent years.
The sales changes of Shanghai sample hospitals were analyzed retrospectively.
Analysis data shows that the average price drop is 79.
5% in the first batch, 74.
1% in the second batch, and 41.
7% in the third batch.
This article uses the first batch of cefuroxime axetil tablets, the second batch of nimesulide dispersible tablets and valacyclovir hydrochloride tablets, and the third batch of rosuvastatin calcium tablets and aripiprazole tablets in recent years.
The sales changes of Shanghai sample hospitals were analyzed retrospectively.
Cefuroxime Axetil Tablets
In April 2015, Shanghai announced the results of the first batch of GPO winning bids.
Only Guangzhou Baiyunshan Tianxin won the bid for cefuroxime axetil tablets.
The winning bid price is 7.
18 yuan per box, 12 pieces, equivalent to about 0.
598 yuan per piece.
Only Guangzhou Baiyunshan Tianxin won the bid for cefuroxime axetil tablets.
The winning bid price is 7.
18 yuan per box, 12 pieces, equivalent to about 0.
598 yuan per piece.
As can be seen from Table 1, Guangzhou Baiyunshan Tianxin’s cefuroxime axetil tablets were not sold in Shanghai in 2014, but after winning the bid in April 2015, the company’s cefuroxime axetil tablets sales continued in 2016-2018.
In the past three years, it has accounted for more than 98% of the Shanghai sample hospital market, and the price in 2015-2019 has remained at 0.
598 yuan.
In the past three years, it has accounted for more than 98% of the Shanghai sample hospital market, and the price in 2015-2019 has remained at 0.
598 yuan.
In September 2019, after the "4+7" expansion and centralized procurement officially opened the bids, there were 3 companies including Sinopharm Zhijun (0.
36 yuan/tablet), Chengdu Beite (0.
48 yuan/tablet), and Jingxin Pharmaceutical (0.
483 yuan/tablet) After winning the bid, Chengdu Better is responsible for supplying the Shanghai market.
Therefore, the sales data for 2020 shows that only Chengdu Better will be the only one, and Guangzhou Baiyunshan Tianxin will withdraw from Shanghai.
36 yuan/tablet), Chengdu Beite (0.
48 yuan/tablet), and Jingxin Pharmaceutical (0.
483 yuan/tablet) After winning the bid, Chengdu Better is responsible for supplying the Shanghai market.
Therefore, the sales data for 2020 shows that only Chengdu Better will be the only one, and Guangzhou Baiyunshan Tianxin will withdraw from Shanghai.
Nimesulide Dispersible Tablets
In October 2016, Shanghai announced the results of the second batch of GPO winning bids.
The only company that won the bid for Nimesulide Dispersible Tablets was Hubei Shubang Pharmaceutical.
The winning bid price is: 50mg is equivalent to 0.
515 yuan per tablet, and 100mg is equivalent to about 0.
876 yuan per tablet.
The only company that won the bid for Nimesulide Dispersible Tablets was Hubei Shubang Pharmaceutical.
The winning bid price is: 50mg is equivalent to 0.
515 yuan per tablet, and 100mg is equivalent to about 0.
876 yuan per tablet.
As can be seen from Table 2, the sales of Hubei Shubang Pharmaceutical Nimesulide Dispersible Tablets in Shanghai sample hospitals were very small from 2015 to 2016, ranking third in 2015, and Kangzhi Pharmaceuticals accounted for an absolute share.
However, after winning the bid in October 2016, Hubei Shubang Pharmaceutical's products accounted for 87.
5% in 2017.
Although Kangzhi Pharmaceutical's Nimesulide dispersible tablets are not the winning product, they are voluntarily supplied at the price of the winning bid with quantity procurement, so they have kept 12.
5% of the share.
Later, Kangzhi Pharmaceuticals proposed that it could not continue to supply at the original price, so it was disqualified from purchasing in January 2019.
From 2018 to 2020, the sales data of Nimesulide dispersible tablets in Shanghai sample hospitals showed that only Hubei Shubang Pharmaceutical, and the price has remained unchanged, indicating that the purchase cycle is still renewed every year after 12 months.
However, after winning the bid in October 2016, Hubei Shubang Pharmaceutical's products accounted for 87.
5% in 2017.
Although Kangzhi Pharmaceutical's Nimesulide dispersible tablets are not the winning product, they are voluntarily supplied at the price of the winning bid with quantity procurement, so they have kept 12.
5% of the share.
Later, Kangzhi Pharmaceuticals proposed that it could not continue to supply at the original price, so it was disqualified from purchasing in January 2019.
From 2018 to 2020, the sales data of Nimesulide dispersible tablets in Shanghai sample hospitals showed that only Hubei Shubang Pharmaceutical, and the price has remained unchanged, indicating that the purchase cycle is still renewed every year after 12 months.
Valaciclovir Hydrochloride Tablets
In October 2016, Shanghai announced the results of the second batch of GPO winning bids, showing that there are two bidding companies for valacyclovir hydrochloride tablets, namely Shanghai Shangyao Xinyi and Chengdu Beite.
The winning bid price of Shanghai Shangyao Xinyi 300mg is equivalent to about 1.
427 yuan per tablet, Chengdu Beite 150mg is equivalent to 0.
835 yuan per tablet, and Chengdu Beite 300mg is equivalent to about 1.
383 yuan per tablet.
The winning bid price of Shanghai Shangyao Xinyi 300mg is equivalent to about 1.
427 yuan per tablet, Chengdu Beite 150mg is equivalent to 0.
835 yuan per tablet, and Chengdu Beite 300mg is equivalent to about 1.
383 yuan per tablet.
It can be seen from Table 3 that from 2015 to 2016, in the Shanghai sample hospital valacyclovir hydrochloride tablet market, there were 7 and 8 companies with sales data, and the sales of the first few companies had little difference.
In 2017, Shanghai Shangyao Xinyi and Chengdu Beite basically occupied the Shanghai market.
In 2018, only these two companies won the bid.
Beginning in November 2018, Chengdu Better’s valacyclovir hydrochloride tablets (300mg, area B) have completed the agreed purchase amount and will no longer continue to supply them.
Shanghai Shangyao Xinyi has expanded its supply to the entire city of Shanghai.
Therefore, in 2019 and 2020, the sales data of valacyclovir hydrochloride tablets in Shanghai sample hospitals show that only Shanghai Shangyao Xinyi, the price of each tablet has remained at 1.
414 yuan for the first three years, indicating that the contract has been renewed every year.
In 2017, Shanghai Shangyao Xinyi and Chengdu Beite basically occupied the Shanghai market.
In 2018, only these two companies won the bid.
Beginning in November 2018, Chengdu Better’s valacyclovir hydrochloride tablets (300mg, area B) have completed the agreed purchase amount and will no longer continue to supply them.
Shanghai Shangyao Xinyi has expanded its supply to the entire city of Shanghai.
Therefore, in 2019 and 2020, the sales data of valacyclovir hydrochloride tablets in Shanghai sample hospitals show that only Shanghai Shangyao Xinyi, the price of each tablet has remained at 1.
414 yuan for the first three years, indicating that the contract has been renewed every year.
Rosuvastatin calcium tablets
In July 2018, Shanghai announced the results of the third batch of GPO winning bids, showing that the only company that won the bid for rosuvastatin calcium tablets was Zhejiang Jingxin Pharmaceutical.
The winning bid price is: 10mg is equivalent to about 3.
061 yuan per tablet; 5mg is equivalent to about 1.
784 yuan per tablet.
The winning bid price is: 10mg is equivalent to about 3.
061 yuan per tablet; 5mg is equivalent to about 1.
784 yuan per tablet.
As can be seen from Table 4, in 2017, the sales of Zhejiang Jingxin's rosuvastatin calcium tablets in Shanghai sample hospitals ranked third after the original research AstraZeneca and the local company Lunanbeit; 2018 It rose to the second place in the year; it rose to the first place in 2019; in 2020, its sales fell to the second place, but AstraZeneca, whose sales volume greatly exceeded the second place, was mainly due to the sharp drop in its price.
In December 2018, in the "4+7" volume purchase, Jingxin Pharmaceutical's rosuvastatin calcium tablet won the bid in the corresponding region at a low price.
The price of 10mg×28 tablets is 21.
8 yuan, which is equivalent to about 0.
779 yuan per tablet.
In September 2019, the "4+7" expansion of centralized procurement, Hisun Pharmaceutical (10mg 0.
20 yuan/tablet, 5mg 0.
10 yuan/tablet), Sandoz (10mg 0.
228 yuan/tablet, 5mg 0.
114 yuan /Tablet) and Zhengda Tianqing (0.
30 yuan/tablet of 10mg) won the bids.
The price of rosuvastatin calcium tablets supplied by Zhejiang Jingxin in Shanghai has been reduced.
The 5mg specification is only 0.
229 yuan, and the 10mg is only 0.
394 yuan, the price is only one-fourth of the original research.
In 2019 and 2020, many companies' rosuvastatin calcium tablets will be sold in Shanghai.
The price of 10mg×28 tablets is 21.
8 yuan, which is equivalent to about 0.
779 yuan per tablet.
In September 2019, the "4+7" expansion of centralized procurement, Hisun Pharmaceutical (10mg 0.
20 yuan/tablet, 5mg 0.
10 yuan/tablet), Sandoz (10mg 0.
228 yuan/tablet, 5mg 0.
114 yuan /Tablet) and Zhengda Tianqing (0.
30 yuan/tablet of 10mg) won the bids.
The price of rosuvastatin calcium tablets supplied by Zhejiang Jingxin in Shanghai has been reduced.
The 5mg specification is only 0.
229 yuan, and the 10mg is only 0.
394 yuan, the price is only one-fourth of the original research.
In 2019 and 2020, many companies' rosuvastatin calcium tablets will be sold in Shanghai.
Aripiprazole Tablets
In July 2018, Shanghai announced the results of the third batch of GPO winning bids.
The winning bidders for aripiprazole tablets were Jiangsu Enhua and Shanghai Shangyao Zhongxi Pharmaceutical.
The winning price of Jiangsu Enhua 10mg is equivalent to about 2.
800 yuan per tablet, and Shanghai Shangyao Zhongxi Pharmaceutical 5mg is equivalent to about 1.
856 yuan per tablet.
The winning bidders for aripiprazole tablets were Jiangsu Enhua and Shanghai Shangyao Zhongxi Pharmaceutical.
The winning price of Jiangsu Enhua 10mg is equivalent to about 2.
800 yuan per tablet, and Shanghai Shangyao Zhongxi Pharmaceutical 5mg is equivalent to about 1.
856 yuan per tablet.
It can be seen from Table 5 that in 2017, Zhejiang Otsuka’s aripiprazole tablets accounted for a major share of the Shanghai sample hospital market, Shanghai Shangyao Zhongxi Pharmaceutical’s sales were smaller than Chengdu Kanghong, and Jiangsu Enhua had no sales data.
After winning the bid in July 2018, Jiangsu Enhua had some sales that year.
In 2019 and 2020, Shanghai Shangyao Zhongxi Pharmaceutical and Jiangsu Enhua ranked second and third in sales, and their combined sales have surpassed Zhejiang Otsuka.
The sales volume of the two companies far exceeds that of Zhejiang Otsuka, mainly because the price of the winning company is very low.
The market shares of the two companies in Shanghai in 2019 and 2020 are 52.
1% and 41.
4%, respectively.
After winning the bid in July 2018, Jiangsu Enhua had some sales that year.
In 2019 and 2020, Shanghai Shangyao Zhongxi Pharmaceutical and Jiangsu Enhua ranked second and third in sales, and their combined sales have surpassed Zhejiang Otsuka.
The sales volume of the two companies far exceeds that of Zhejiang Otsuka, mainly because the price of the winning company is very low.
The market shares of the two companies in Shanghai in 2019 and 2020 are 52.
1% and 41.
4%, respectively.
Summary <<<
From the perspective of the three batches of GPO procurement, the first two batches of volume procurement documents have clearly restricted the procurement and use of drugs by companies that have not won the bid.
They are unwilling to adjust the price to the unsuccessful varieties that are not higher than the bid price of the volume procurement.
Medical insurance is sold by designated medical institutions.
According to data from PDB Shanghai sample hospitals, the market share of the winning bidders has changed significantly, and the winning bidder will eventually occupy the entire market share of the product.
They are unwilling to adjust the price to the unsuccessful varieties that are not higher than the bid price of the volume procurement.
Medical insurance is sold by designated medical institutions.
According to data from PDB Shanghai sample hospitals, the market share of the winning bidders has changed significantly, and the winning bidder will eventually occupy the entire market share of the product.
The third batch of GPOs relaxed restrictions on the unsuccessful products, only promising 50% of the market share of the winning company, and the unsuccessful products do not need to be reduced to the successful bid price for mass purchases, they can be sold in medical institutions, and there is a chance to seize the remaining 50 % Share.
The third batch of bulk procurement plans comprehensively considers the actual needs of clinical use, relaxes restrictions on the products that have not won the bid, provides space for the sales of original research products, and also provides buffer space for policy implementation.
The third batch of bulk procurement plans comprehensively considers the actual needs of clinical use, relaxes restrictions on the products that have not won the bid, provides space for the sales of original research products, and also provides buffer space for policy implementation.
Under the volume purchase model, the sales model of pharmaceutical companies has undergone a fundamental change.
For areas and varieties that carry out mass procurement, the sales expenses required for academic promotion and hospital promotion may be greatly reduced, and the value of cost control capabilities will gradually be reflected.
For areas and varieties that carry out mass procurement, the sales expenses required for academic promotion and hospital promotion may be greatly reduced, and the value of cost control capabilities will gradually be reflected.
Shanghai has accumulated local experience through the pilot volume procurement, and gradually expanded to "4+7" urban volume procurement, "4+7" expanded volume procurement and national volume procurement.
The national volume procurement policy is based on Shanghai On the basis of the municipal procurement policy with volume, a certain degree of modification and improvement has been made, which is a major reform of the existing non-volume bidding procurement policy.
Up to now, the first four batches of national procurement have been carried out, covering 190 varieties.
It can be said that Shanghai's pilot project with volume procurement has been relatively successful.
The national volume procurement policy is based on Shanghai On the basis of the municipal procurement policy with volume, a certain degree of modification and improvement has been made, which is a major reform of the existing non-volume bidding procurement policy.
Up to now, the first four batches of national procurement have been carried out, covering 190 varieties.
It can be said that Shanghai's pilot project with volume procurement has been relatively successful.
Pharmaceutical Network News on June 4 A few days ago, Quanyao.
com released the "Notice on Carrying out Part One of the Pharmaceutical Group Procurement Catalogue of Shenzhen Public Hospitals (Second Batch) (1) 2021 Pharmaceutical Group Procurement Registration", Shenzhen GPO's second Batch catalog procurement was officially launched.
com released the "Notice on Carrying out Part One of the Pharmaceutical Group Procurement Catalogue of Shenzhen Public Hospitals (Second Batch) (1) 2021 Pharmaceutical Group Procurement Registration", Shenzhen GPO's second Batch catalog procurement was officially launched.
According to the documents, the registration date is May 28th-June 7th, 2021 at 17:30.
According to combing, this GPO involves 140 varieties and 154 product specifications.
Among them, injections account for more than half, involving 75 product specifications and 70 varieties.
Followed by oral regular-release agents, involving 49 varieties.
According to combing, this GPO involves 140 varieties and 154 product specifications.
Among them, injections account for more than half, involving 75 product specifications and 70 varieties.
Followed by oral regular-release agents, involving 49 varieties.
The Group Purchasing Organization (GPO) is a third-party intermediary organization for social procurement.
By providing product bidding services, it can obtain lower prices than a single hospital procurement and help hospitals save procurement costs.
At the same time, through the provision of specialization, standardization of supply chain management services to help pharmaceutical production enterprises and hospitals together to improve supply chain operational efficiency, reduce operating costs, bring more revenue for the hospital.
By providing product bidding services, it can obtain lower prices than a single hospital procurement and help hospitals save procurement costs.
At the same time, through the provision of specialization, standardization of supply chain management services to help pharmaceutical production enterprises and hospitals together to improve supply chain operational efficiency, reduce operating costs, bring more revenue for the hospital.
As a pioneer in GPO procurement, Shanghai has completed three batches of volume procurement since it launched the first batch of GPOs in December 2014.
Analysis data shows that the average price drop is 79.
5% in the first batch, 74.
1% in the second batch, and 41.
7% in the third batch.
This article uses the first batch of cefuroxime axetil tablets, the second batch of nimesulide dispersible tablets and valacyclovir hydrochloride tablets, and the third batch of rosuvastatin calcium tablets and aripiprazole tablets in recent years.
The sales changes of Shanghai sample hospitals were analyzed retrospectively.
Analysis data shows that the average price drop is 79.
5% in the first batch, 74.
1% in the second batch, and 41.
7% in the third batch.
This article uses the first batch of cefuroxime axetil tablets, the second batch of nimesulide dispersible tablets and valacyclovir hydrochloride tablets, and the third batch of rosuvastatin calcium tablets and aripiprazole tablets in recent years.
The sales changes of Shanghai sample hospitals were analyzed retrospectively.
Cefuroxime Axetil Tablets
In April 2015, Shanghai announced the results of the first batch of GPO winning bids.
Only Guangzhou Baiyunshan Tianxin won the bid for cefuroxime axetil tablets.
The winning bid price is 7.
18 yuan per box, 12 pieces, equivalent to about 0.
598 yuan per piece.
Only Guangzhou Baiyunshan Tianxin won the bid for cefuroxime axetil tablets.
The winning bid price is 7.
18 yuan per box, 12 pieces, equivalent to about 0.
598 yuan per piece.
As can be seen from Table 1, Guangzhou Baiyunshan Tianxin’s cefuroxime axetil tablets were not sold in Shanghai in 2014, but after winning the bid in April 2015, the company’s cefuroxime axetil tablets sales continued in 2016-2018.
In the past three years, it has accounted for more than 98% of the Shanghai sample hospital market, and the price in 2015-2019 has remained at 0.
598 yuan.
In the past three years, it has accounted for more than 98% of the Shanghai sample hospital market, and the price in 2015-2019 has remained at 0.
598 yuan.
In September 2019, after the "4+7" expansion and centralized procurement officially opened the bids, there were 3 companies including Sinopharm Zhijun (0.
36 yuan/tablet), Chengdu Beite (0.
48 yuan/tablet), and Jingxin Pharmaceutical (0.
483 yuan/tablet) After winning the bid, Chengdu Better is responsible for supplying the Shanghai market.
Therefore, the sales data for 2020 shows that only Chengdu Better will be the only one, and Guangzhou Baiyunshan Tianxin will withdraw from Shanghai.
36 yuan/tablet), Chengdu Beite (0.
48 yuan/tablet), and Jingxin Pharmaceutical (0.
483 yuan/tablet) After winning the bid, Chengdu Better is responsible for supplying the Shanghai market.
Therefore, the sales data for 2020 shows that only Chengdu Better will be the only one, and Guangzhou Baiyunshan Tianxin will withdraw from Shanghai.
Nimesulide Dispersible Tablets
In October 2016, Shanghai announced the results of the second batch of GPO winning bids.
The only company that won the bid for Nimesulide Dispersible Tablets was Hubei Shubang Pharmaceutical.
The winning bid price is: 50mg is equivalent to 0.
515 yuan per tablet, and 100mg is equivalent to about 0.
876 yuan per tablet.
The only company that won the bid for Nimesulide Dispersible Tablets was Hubei Shubang Pharmaceutical.
The winning bid price is: 50mg is equivalent to 0.
515 yuan per tablet, and 100mg is equivalent to about 0.
876 yuan per tablet.
As can be seen from Table 2, the sales of Hubei Shubang Pharmaceutical Nimesulide Dispersible Tablets in Shanghai sample hospitals were very small from 2015 to 2016, ranking third in 2015, and Kangzhi Pharmaceuticals accounted for an absolute share.
However, after winning the bid in October 2016, Hubei Shubang Pharmaceutical's products accounted for 87.
5% in 2017.
Although Kangzhi Pharmaceutical's Nimesulide dispersible tablets are not the winning product, they are voluntarily supplied at the price of the winning bid with quantity procurement, so they have kept 12.
5% of the share.
Later, Kangzhi Pharmaceuticals proposed that it could not continue to supply at the original price, so it was disqualified from purchasing in January 2019.
From 2018 to 2020, the sales data of Nimesulide dispersible tablets in Shanghai sample hospitals showed that only Hubei Shubang Pharmaceutical, and the price has remained unchanged, indicating that the purchase cycle is still renewed every year after 12 months.
However, after winning the bid in October 2016, Hubei Shubang Pharmaceutical's products accounted for 87.
5% in 2017.
Although Kangzhi Pharmaceutical's Nimesulide dispersible tablets are not the winning product, they are voluntarily supplied at the price of the winning bid with quantity procurement, so they have kept 12.
5% of the share.
Later, Kangzhi Pharmaceuticals proposed that it could not continue to supply at the original price, so it was disqualified from purchasing in January 2019.
From 2018 to 2020, the sales data of Nimesulide dispersible tablets in Shanghai sample hospitals showed that only Hubei Shubang Pharmaceutical, and the price has remained unchanged, indicating that the purchase cycle is still renewed every year after 12 months.
Valaciclovir Hydrochloride Tablets
In October 2016, Shanghai announced the results of the second batch of GPO winning bids, showing that there are two bidding companies for valacyclovir hydrochloride tablets, namely Shanghai Shangyao Xinyi and Chengdu Beite.
The winning bid price of Shanghai Shangyao Xinyi 300mg is equivalent to about 1.
427 yuan per tablet, Chengdu Beite 150mg is equivalent to 0.
835 yuan per tablet, and Chengdu Beite 300mg is equivalent to about 1.
383 yuan per tablet.
The winning bid price of Shanghai Shangyao Xinyi 300mg is equivalent to about 1.
427 yuan per tablet, Chengdu Beite 150mg is equivalent to 0.
835 yuan per tablet, and Chengdu Beite 300mg is equivalent to about 1.
383 yuan per tablet.
It can be seen from Table 3 that from 2015 to 2016, in the Shanghai sample hospital valacyclovir hydrochloride tablet market, there were 7 and 8 companies with sales data, and the sales of the first few companies had little difference.
In 2017, Shanghai Shangyao Xinyi and Chengdu Beite basically occupied the Shanghai market.
In 2018, only these two companies won the bid.
Beginning in November 2018, Chengdu Better’s valacyclovir hydrochloride tablets (300mg, area B) have completed the agreed purchase amount and will no longer continue to supply them.
Shanghai Shangyao Xinyi has expanded its supply to the entire city of Shanghai.
Therefore, in 2019 and 2020, the sales data of valacyclovir hydrochloride tablets in Shanghai sample hospitals show that only Shanghai Shangyao Xinyi, the price of each tablet has remained at 1.
414 yuan for the first three years, indicating that the contract has been renewed every year.
In 2017, Shanghai Shangyao Xinyi and Chengdu Beite basically occupied the Shanghai market.
In 2018, only these two companies won the bid.
Beginning in November 2018, Chengdu Better’s valacyclovir hydrochloride tablets (300mg, area B) have completed the agreed purchase amount and will no longer continue to supply them.
Shanghai Shangyao Xinyi has expanded its supply to the entire city of Shanghai.
Therefore, in 2019 and 2020, the sales data of valacyclovir hydrochloride tablets in Shanghai sample hospitals show that only Shanghai Shangyao Xinyi, the price of each tablet has remained at 1.
414 yuan for the first three years, indicating that the contract has been renewed every year.
Rosuvastatin calcium tablets
In July 2018, Shanghai announced the results of the third batch of GPO winning bids, showing that the only company that won the bid for rosuvastatin calcium tablets was Zhejiang Jingxin Pharmaceutical.
The winning bid price is: 10mg is equivalent to about 3.
061 yuan per tablet; 5mg is equivalent to about 1.
784 yuan per tablet.
The winning bid price is: 10mg is equivalent to about 3.
061 yuan per tablet; 5mg is equivalent to about 1.
784 yuan per tablet.
As can be seen from Table 4, in 2017, the sales of Zhejiang Jingxin's rosuvastatin calcium tablets in Shanghai sample hospitals ranked third after the original research AstraZeneca and the local company Lunanbeit; 2018 It rose to the second place in the year; it rose to the first place in 2019; in 2020, its sales fell to the second place, but AstraZeneca, whose sales volume greatly exceeded the second place, was mainly due to the sharp drop in its price.
In December 2018, in the "4+7" volume purchase, Jingxin Pharmaceutical's rosuvastatin calcium tablet won the bid in the corresponding region at a low price.
The price of 10mg×28 tablets is 21.
8 yuan, which is equivalent to about 0.
779 yuan per tablet.
In September 2019, the "4+7" expansion of centralized procurement, Hisun Pharmaceutical (10mg 0.
20 yuan/tablet, 5mg 0.
10 yuan/tablet), Sandoz (10mg 0.
228 yuan/tablet, 5mg 0.
114 yuan /Tablet) and Zhengda Tianqing (0.
30 yuan/tablet of 10mg) won the bids.
The price of rosuvastatin calcium tablets supplied by Zhejiang Jingxin in Shanghai has been reduced.
The 5mg specification is only 0.
229 yuan, and the 10mg is only 0.
394 yuan, the price is only one-fourth of the original research.
In 2019 and 2020, many companies' rosuvastatin calcium tablets will be sold in Shanghai.
The price of 10mg×28 tablets is 21.
8 yuan, which is equivalent to about 0.
779 yuan per tablet.
In September 2019, the "4+7" expansion of centralized procurement, Hisun Pharmaceutical (10mg 0.
20 yuan/tablet, 5mg 0.
10 yuan/tablet), Sandoz (10mg 0.
228 yuan/tablet, 5mg 0.
114 yuan /Tablet) and Zhengda Tianqing (0.
30 yuan/tablet of 10mg) won the bids.
The price of rosuvastatin calcium tablets supplied by Zhejiang Jingxin in Shanghai has been reduced.
The 5mg specification is only 0.
229 yuan, and the 10mg is only 0.
394 yuan, the price is only one-fourth of the original research.
In 2019 and 2020, many companies' rosuvastatin calcium tablets will be sold in Shanghai.
Aripiprazole Tablets
In July 2018, Shanghai announced the results of the third batch of GPO winning bids.
The winning bidders for aripiprazole tablets were Jiangsu Enhua and Shanghai Shangyao Zhongxi Pharmaceutical.
The winning price of Jiangsu Enhua 10mg is equivalent to about 2.
800 yuan per tablet, and Shanghai Shangyao Zhongxi Pharmaceutical 5mg is equivalent to about 1.
856 yuan per tablet.
The winning bidders for aripiprazole tablets were Jiangsu Enhua and Shanghai Shangyao Zhongxi Pharmaceutical.
The winning price of Jiangsu Enhua 10mg is equivalent to about 2.
800 yuan per tablet, and Shanghai Shangyao Zhongxi Pharmaceutical 5mg is equivalent to about 1.
856 yuan per tablet.
It can be seen from Table 5 that in 2017, Zhejiang Otsuka’s aripiprazole tablets accounted for a major share of the Shanghai sample hospital market, Shanghai Shangyao Zhongxi Pharmaceutical’s sales were smaller than Chengdu Kanghong, and Jiangsu Enhua had no sales data.
After winning the bid in July 2018, Jiangsu Enhua had some sales that year.
In 2019 and 2020, Shanghai Shangyao Zhongxi Pharmaceutical and Jiangsu Enhua ranked second and third in sales, and their combined sales have surpassed Zhejiang Otsuka.
The sales volume of the two companies far exceeds that of Zhejiang Otsuka, mainly because the price of the winning company is very low.
The market shares of the two companies in Shanghai in 2019 and 2020 are 52.
1% and 41.
4%, respectively.
After winning the bid in July 2018, Jiangsu Enhua had some sales that year.
In 2019 and 2020, Shanghai Shangyao Zhongxi Pharmaceutical and Jiangsu Enhua ranked second and third in sales, and their combined sales have surpassed Zhejiang Otsuka.
The sales volume of the two companies far exceeds that of Zhejiang Otsuka, mainly because the price of the winning company is very low.
The market shares of the two companies in Shanghai in 2019 and 2020 are 52.
1% and 41.
4%, respectively.
Summary <<<
From the perspective of the three batches of GPO procurement, the first two batches of volume procurement documents have clearly restricted the procurement and use of drugs by companies that have not won the bid.
They are unwilling to adjust the price to the unsuccessful varieties that are not higher than the bid price of the volume procurement.
Medical insurance is sold by designated medical institutions.
According to data from PDB Shanghai sample hospitals, the market share of the winning bidders has changed significantly, and the winning bidder will eventually occupy the entire market share of the product.
They are unwilling to adjust the price to the unsuccessful varieties that are not higher than the bid price of the volume procurement.
Medical insurance is sold by designated medical institutions.
According to data from PDB Shanghai sample hospitals, the market share of the winning bidders has changed significantly, and the winning bidder will eventually occupy the entire market share of the product.
The third batch of GPOs relaxed restrictions on the unsuccessful products, only promising 50% of the market share of the winning company, and the unsuccessful products do not need to be reduced to the successful bid price for mass purchases, they can be sold in medical institutions, and there is a chance to seize the remaining 50 % Share.
The third batch of bulk procurement plans comprehensively considers the actual needs of clinical use, relaxes restrictions on the products that have not won the bid, provides space for the sales of original research products, and also provides buffer space for policy implementation.
The third batch of bulk procurement plans comprehensively considers the actual needs of clinical use, relaxes restrictions on the products that have not won the bid, provides space for the sales of original research products, and also provides buffer space for policy implementation.
Under the volume purchase model, the sales model of pharmaceutical companies has undergone a fundamental change.
For areas and varieties that carry out mass procurement, the sales expenses required for academic promotion and hospital promotion may be greatly reduced, and the value of cost control capabilities will gradually be reflected.
For areas and varieties that carry out mass procurement, the sales expenses required for academic promotion and hospital promotion may be greatly reduced, and the value of cost control capabilities will gradually be reflected.
Shanghai has accumulated local experience through the pilot volume procurement, and gradually expanded to "4+7" urban volume procurement, "4+7" expanded volume procurement and national volume procurement.
The national volume procurement policy is based on Shanghai On the basis of the municipal procurement policy with volume, a certain degree of modification and improvement has been made, which is a major reform of the existing non-volume bidding procurement policy.
Up to now, the first four batches of national procurement have been carried out, covering 190 varieties.
It can be said that Shanghai's pilot project with volume procurement has been relatively successful.
The national volume procurement policy is based on Shanghai On the basis of the municipal procurement policy with volume, a certain degree of modification and improvement has been made, which is a major reform of the existing non-volume bidding procurement policy.
Up to now, the first four batches of national procurement have been carried out, covering 190 varieties.
It can be said that Shanghai's pilot project with volume procurement has been relatively successful.
Pharmaceutical Network News on June 4 A few days ago, Quanyao.
com released the "Notice on Carrying out Part One of the Pharmaceutical Group Procurement Catalogue of Shenzhen Public Hospitals (Second Batch) (1) 2021 Pharmaceutical Group Procurement Registration", Shenzhen GPO's second Batch catalog procurement was officially launched.
com released the "Notice on Carrying out Part One of the Pharmaceutical Group Procurement Catalogue of Shenzhen Public Hospitals (Second Batch) (1) 2021 Pharmaceutical Group Procurement Registration", Shenzhen GPO's second Batch catalog procurement was officially launched.
According to the documents, the registration date is May 28th-June 7th, 2021 at 17:30.
According to combing, this GPO involves 140 varieties and 154 product specifications.
Among them, injections account for more than half, involving 75 product specifications and 70 varieties.
Followed by oral regular-release agents, involving 49 varieties.
According to combing, this GPO involves 140 varieties and 154 product specifications.
Among them, injections account for more than half, involving 75 product specifications and 70 varieties.
Followed by oral regular-release agents, involving 49 varieties.
The Group Purchasing Organization (GPO) is a third-party intermediary organization for social procurement.
By providing product bidding services, it can obtain lower prices than a single hospital procurement and help hospitals save procurement costs.
At the same time, through the provision of specialization, standardization of supply chain management services to help pharmaceutical production enterprises and hospitals together to improve supply chain operational efficiency, reduce operating costs, bring more revenue for the hospital.
Drugs Drugs Drugs enterprise business enterprise Hospital Hospital HospitalBy providing product bidding services, it can obtain lower prices than a single hospital procurement and help hospitals save procurement costs.
At the same time, through the provision of specialization, standardization of supply chain management services to help pharmaceutical production enterprises and hospitals together to improve supply chain operational efficiency, reduce operating costs, bring more revenue for the hospital.
As a pioneer in GPO procurement, Shanghai has completed three batches of volume procurement since it launched the first batch of GPOs in December 2014.
Analysis data shows that the average price drop is 79.
5% in the first batch, 74.
1% in the second batch, and 41.
7% in the third batch.
This article uses the first batch of cefuroxime axetil tablets, the second batch of nimesulide dispersible tablets and valacyclovir hydrochloride tablets, and the third batch of rosuvastatin calcium tablets and aripiprazole tablets in recent years.
The sales changes of Shanghai sample hospitals were analyzed retrospectively.
Analysis data shows that the average price drop is 79.
5% in the first batch, 74.
1% in the second batch, and 41.
7% in the third batch.
This article uses the first batch of cefuroxime axetil tablets, the second batch of nimesulide dispersible tablets and valacyclovir hydrochloride tablets, and the third batch of rosuvastatin calcium tablets and aripiprazole tablets in recent years.
The sales changes of Shanghai sample hospitals were analyzed retrospectively.
Cefuroxime Axetil Tablets
Cefuroxime Axetil Tablets In April 2015, Shanghai announced the results of the first batch of GPO winning bids.
Only Guangzhou Baiyunshan Tianxin won the bid for cefuroxime axetil tablets.
The winning bid price is 7.
18 yuan per box, 12 pieces, equivalent to about 0.
598 yuan per piece.
Only Guangzhou Baiyunshan Tianxin won the bid for cefuroxime axetil tablets.
The winning bid price is 7.
18 yuan per box, 12 pieces, equivalent to about 0.
598 yuan per piece.
As can be seen from Table 1, Guangzhou Baiyunshan Tianxin’s cefuroxime axetil tablets were not sold in Shanghai in 2014, but after winning the bid in April 2015, the company’s cefuroxime axetil tablets sales continued in 2016-2018.
In the past three years, it has accounted for more than 98% of the Shanghai sample hospital market, and the price in 2015-2019 has remained at 0.
598 yuan.
In the past three years, it has accounted for more than 98% of the Shanghai sample hospital market, and the price in 2015-2019 has remained at 0.
598 yuan.
In September 2019, after the "4+7" expansion and centralized procurement officially opened the bids, there were 3 companies including Sinopharm Zhijun (0.
36 yuan/tablet), Chengdu Beite (0.
48 yuan/tablet), and Jingxin Pharmaceutical (0.
483 yuan/tablet) After winning the bid, Chengdu Better is responsible for supplying the Shanghai market.
Therefore, the sales data for 2020 shows that only Chengdu Better will be the only one, and Guangzhou Baiyunshan Tianxin will withdraw from Shanghai.
36 yuan/tablet), Chengdu Beite (0.
48 yuan/tablet), and Jingxin Pharmaceutical (0.
483 yuan/tablet) After winning the bid, Chengdu Better is responsible for supplying the Shanghai market.
Therefore, the sales data for 2020 shows that only Chengdu Better will be the only one, and Guangzhou Baiyunshan Tianxin will withdraw from Shanghai.
Nimesulide Dispersible Tablets
Nimesulide Dispersible Tablets In October 2016, Shanghai announced the results of the second batch of GPO winning bids.
The only company that won the bid for Nimesulide Dispersible Tablets was Hubei Shubang Pharmaceutical.
The winning bid price is: 50mg is equivalent to 0.
515 yuan per tablet, and 100mg is equivalent to about 0.
876 yuan per tablet.
The only company that won the bid for Nimesulide Dispersible Tablets was Hubei Shubang Pharmaceutical.
The winning bid price is: 50mg is equivalent to 0.
515 yuan per tablet, and 100mg is equivalent to about 0.
876 yuan per tablet.
As can be seen from Table 2, the sales of Hubei Shubang Pharmaceutical Nimesulide Dispersible Tablets in Shanghai sample hospitals were very small from 2015 to 2016, ranking third in 2015, and Kangzhi Pharmaceuticals accounted for an absolute share.
However, after winning the bid in October 2016, Hubei Shubang Pharmaceutical's products accounted for 87.
5% in 2017.
Although Kangzhi Pharmaceutical's Nimesulide dispersible tablets are not the winning product, they are voluntarily supplied at the price of the winning bid with quantity procurement, so they have kept 12.
5% of the share.
Later, Kangzhi Pharmaceuticals proposed that it could not continue to supply at the original price, so it was disqualified from purchasing in January 2019.
From 2018 to 2020, the sales data of Nimesulide dispersible tablets in Shanghai sample hospitals showed that only Hubei Shubang Pharmaceutical, and the price has remained unchanged, indicating that the purchase cycle is still renewed every year after 12 months.
However, after winning the bid in October 2016, Hubei Shubang Pharmaceutical's products accounted for 87.
5% in 2017.
Although Kangzhi Pharmaceutical's Nimesulide dispersible tablets are not the winning product, they are voluntarily supplied at the price of the winning bid with quantity procurement, so they have kept 12.
5% of the share.
Later, Kangzhi Pharmaceuticals proposed that it could not continue to supply at the original price, so it was disqualified from purchasing in January 2019.
From 2018 to 2020, the sales data of Nimesulide dispersible tablets in Shanghai sample hospitals showed that only Hubei Shubang Pharmaceutical, and the price has remained unchanged, indicating that the purchase cycle is still renewed every year after 12 months.
Valaciclovir Hydrochloride Tablets
Valaciclovir Hydrochloride Tablets In October 2016, Shanghai announced the results of the second batch of GPO winning bids, showing that there are two bidding companies for valacyclovir hydrochloride tablets, namely Shanghai Shangyao Xinyi and Chengdu Beite.
The winning bid price of Shanghai Shangyao Xinyi 300mg is equivalent to about 1.
427 yuan per tablet, Chengdu Beite 150mg is equivalent to 0.
835 yuan per tablet, and Chengdu Beite 300mg is equivalent to about 1.
383 yuan per tablet.
The winning bid price of Shanghai Shangyao Xinyi 300mg is equivalent to about 1.
427 yuan per tablet, Chengdu Beite 150mg is equivalent to 0.
835 yuan per tablet, and Chengdu Beite 300mg is equivalent to about 1.
383 yuan per tablet.
It can be seen from Table 3 that from 2015 to 2016, in the Shanghai sample hospital valacyclovir hydrochloride tablet market, there were 7 and 8 companies with sales data, and the sales of the first few companies had little difference.
In 2017, Shanghai Shangyao Xinyi and Chengdu Beite basically occupied the Shanghai market.
In 2018, only these two companies won the bid.
Beginning in November 2018, Chengdu Better’s valacyclovir hydrochloride tablets (300mg, area B) have completed the agreed purchase amount and will no longer continue to supply them.
Shanghai Shangyao Xinyi has expanded its supply to the entire city of Shanghai.
Therefore, in 2019 and 2020, the sales data of valacyclovir hydrochloride tablets in Shanghai sample hospitals show that only Shanghai Shangyao Xinyi, the price of each tablet has remained at 1.
414 yuan for the first three years, indicating that the contract has been renewed every year.
In 2017, Shanghai Shangyao Xinyi and Chengdu Beite basically occupied the Shanghai market.
In 2018, only these two companies won the bid.
Beginning in November 2018, Chengdu Better’s valacyclovir hydrochloride tablets (300mg, area B) have completed the agreed purchase amount and will no longer continue to supply them.
Shanghai Shangyao Xinyi has expanded its supply to the entire city of Shanghai.
Therefore, in 2019 and 2020, the sales data of valacyclovir hydrochloride tablets in Shanghai sample hospitals show that only Shanghai Shangyao Xinyi, the price of each tablet has remained at 1.
414 yuan for the first three years, indicating that the contract has been renewed every year.
Rosuvastatin calcium tablets
Rosuvastatin calcium tablets In July 2018, Shanghai announced the results of the third batch of GPO winning bids, showing that the only company that won the bid for rosuvastatin calcium tablets was Zhejiang Jingxin Pharmaceutical.
The winning bid price is: 10mg is equivalent to about 3.
061 yuan per tablet; 5mg is equivalent to about 1.
784 yuan per tablet.
The winning bid price is: 10mg is equivalent to about 3.
061 yuan per tablet; 5mg is equivalent to about 1.
784 yuan per tablet.
As can be seen from Table 4, in 2017, the sales of Zhejiang Jingxin's rosuvastatin calcium tablets in Shanghai sample hospitals ranked third after the original research AstraZeneca and the local company Lunanbeit; 2018 It rose to the second place in the year; it rose to the first place in 2019; in 2020, its sales fell to the second place, but AstraZeneca, whose sales volume greatly exceeded the second place, was mainly due to the sharp drop in its price.
In December 2018, in the "4+7" volume purchase, Jingxin Pharmaceutical's rosuvastatin calcium tablet won the bid in the corresponding region at a low price.
The price of 10mg×28 tablets is 21.
8 yuan, which is equivalent to about 0.
779 yuan per tablet.
In September 2019, the "4+7" expansion of centralized procurement, Hisun Pharmaceutical (10mg 0.
20 yuan/tablet, 5mg 0.
10 yuan/tablet), Sandoz (10mg 0.
228 yuan/tablet, 5mg 0.
114 yuan /Tablet) and Zhengda Tianqing (0.
30 yuan/tablet of 10mg) won the bids.
The price of rosuvastatin calcium tablets supplied by Zhejiang Jingxin in Shanghai has been reduced.
The 5mg specification is only 0.
229 yuan, and the 10mg is only 0.
394 yuan, the price is only one-fourth of the original research.
In 2019 and 2020, many companies' rosuvastatin calcium tablets will be sold in Shanghai.
The price of 10mg×28 tablets is 21.
8 yuan, which is equivalent to about 0.
779 yuan per tablet.
In September 2019, the "4+7" expansion of centralized procurement, Hisun Pharmaceutical (10mg 0.
20 yuan/tablet, 5mg 0.
10 yuan/tablet), Sandoz (10mg 0.
228 yuan/tablet, 5mg 0.
114 yuan /Tablet) and Zhengda Tianqing (0.
30 yuan/tablet of 10mg) won the bids.
The price of rosuvastatin calcium tablets supplied by Zhejiang Jingxin in Shanghai has been reduced.
The 5mg specification is only 0.
229 yuan, and the 10mg is only 0.
394 yuan, the price is only one-fourth of the original research.
In 2019 and 2020, many companies' rosuvastatin calcium tablets will be sold in Shanghai.
Aripiprazole Tablets
Aripiprazole Tablets In July 2018, Shanghai announced the results of the third batch of GPO winning bids.
The winning bidders for aripiprazole tablets were Jiangsu Enhua and Shanghai Shangyao Zhongxi Pharmaceutical.
The winning price of Jiangsu Enhua 10mg is equivalent to about 2.
800 yuan per tablet, and Shanghai Shangyao Zhongxi Pharmaceutical 5mg is equivalent to about 1.
856 yuan per tablet.
The winning bidders for aripiprazole tablets were Jiangsu Enhua and Shanghai Shangyao Zhongxi Pharmaceutical.
The winning price of Jiangsu Enhua 10mg is equivalent to about 2.
800 yuan per tablet, and Shanghai Shangyao Zhongxi Pharmaceutical 5mg is equivalent to about 1.
856 yuan per tablet.
It can be seen from Table 5 that in 2017, Zhejiang Otsuka’s aripiprazole tablets accounted for a major share of the Shanghai sample hospital market, Shanghai Shangyao Zhongxi Pharmaceutical’s sales were smaller than Chengdu Kanghong, and Jiangsu Enhua had no sales data.
After winning the bid in July 2018, Jiangsu Enhua had some sales that year.
In 2019 and 2020, Shanghai Shangyao Zhongxi Pharmaceutical and Jiangsu Enhua ranked second and third in sales, and their combined sales have surpassed Zhejiang Otsuka.
The sales volume of the two companies far exceeds that of Zhejiang Otsuka, mainly because the price of the winning company is very low.
The market shares of the two companies in Shanghai in 2019 and 2020 are 52.
1% and 41.
4%, respectively.
After winning the bid in July 2018, Jiangsu Enhua had some sales that year.
In 2019 and 2020, Shanghai Shangyao Zhongxi Pharmaceutical and Jiangsu Enhua ranked second and third in sales, and their combined sales have surpassed Zhejiang Otsuka.
The sales volume of the two companies far exceeds that of Zhejiang Otsuka, mainly because the price of the winning company is very low.
The market shares of the two companies in Shanghai in 2019 and 2020 are 52.
1% and 41.
4%, respectively.
Summary <<<
Summary <<< From the perspective of the three batches of GPO procurement, the first two batches of volume procurement documents have clearly restricted the procurement and use of drugs by companies that have not won the bid.
They are unwilling to adjust the price to the unsuccessful varieties that are not higher than the bid price of the volume procurement.
Medical insurance is sold by designated medical institutions.
According to data from PDB Shanghai sample hospitals, the market share of the winning bidders has changed significantly, and the winning bidder will eventually occupy the entire market share of the product.
They are unwilling to adjust the price to the unsuccessful varieties that are not higher than the bid price of the volume procurement.
Medical insurance is sold by designated medical institutions.
According to data from PDB Shanghai sample hospitals, the market share of the winning bidders has changed significantly, and the winning bidder will eventually occupy the entire market share of the product.
The third batch of GPOs relaxed restrictions on the unsuccessful products, only promising 50% of the market share of the winning company, and the unsuccessful products do not need to be reduced to the successful bid price for mass purchases, they can be sold in medical institutions, and there is a chance to seize the remaining 50 % Share.
The third batch of bulk procurement plans comprehensively considers the actual needs of clinical use, relaxes restrictions on the products that have not won the bid, provides space for the sales of original research products, and also provides buffer space for policy implementation.
The third batch of bulk procurement plans comprehensively considers the actual needs of clinical use, relaxes restrictions on the products that have not won the bid, provides space for the sales of original research products, and also provides buffer space for policy implementation.
Under the volume purchase model, the sales model of pharmaceutical companies has undergone a fundamental change.
For areas and varieties that carry out mass procurement, the sales expenses required for academic promotion and hospital promotion may be greatly reduced, and the value of cost control capabilities will gradually be reflected.
For areas and varieties that carry out mass procurement, the sales expenses required for academic promotion and hospital promotion may be greatly reduced, and the value of cost control capabilities will gradually be reflected.
Shanghai has accumulated local experience through the pilot volume procurement, and gradually expanded to "4+7" urban volume procurement, "4+7" expanded volume procurement and national volume procurement.
The national volume procurement policy is based on Shanghai On the basis of the municipal procurement policy with volume, a certain degree of modification and improvement has been made, which is a major reform of the existing non-volume bidding procurement policy.
Up to now, the first four batches of national procurement have been carried out, covering 190 varieties.
It can be said that Shanghai's pilot project with volume procurement has been relatively successful.
Bidding procurement bidding bidding procurement procurement The national volume procurement policy is based on Shanghai On the basis of the municipal procurement policy with volume, a certain degree of modification and improvement has been made, which is a major reform of the existing non-volume bidding procurement policy.
Up to now, the first four batches of national procurement have been carried out, covering 190 varieties.
It can be said that Shanghai's pilot project with volume procurement has been relatively successful.
